Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Economic impact of enoxaparin after acute ischemic stroke based on PREVAIL.

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L.

Clin Appl Thromb Hemost. 2011 Apr;17(2):150-7. doi: 10.1177/1076029610389026. Epub 2010 Dec 15.

PMID:
21159705
2.

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L.

J Hosp Med. 2012 Mar;7(3):176-82. doi: 10.1002/jhm.968. Epub 2011 Nov 4.

PMID:
22058011
3.

Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study.

Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF; PREVAIL Investigators.

Stroke. 2009 Nov;40(11):3532-40. doi: 10.1161/STROKEAHA.109.555003. Epub 2009 Aug 20.

4.

Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

Amin AN, Lin J, Lenhart G, Schulman KL.

Thromb Haemost. 2009 Aug;102(2):321-6. doi: 10.1160/TH09-03-0147.

PMID:
19652883
5.

Hospital-based costs associated with venous thromboembolism prophylaxis regimens.

Merli G, Ferrufino CP, Lin J, Hussein M, Battleman D.

J Thromb Thrombolysis. 2010 May;29(4):449-58. doi: 10.1007/s11239-009-0371-x.

PMID:
19847624
6.

Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany.

Schädlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG.

Am J Cardiovasc Drugs. 2007;7(3):199-217.

PMID:
17610347
7.

Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.

Deitelzweig SB, Becker R, Lin J, Benner J.

Thromb Haemost. 2008 Nov;100(5):810-20.

PMID:
18989525
8.

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients.

Pineo GF, Lin J, Annemans L.

Clinicoecon Outcomes Res. 2012;4:99-107. doi: 10.2147/CEOR.S30857. Epub 2012 Apr 23.

9.
10.

Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.

Hillbom M, Erilä T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M.

Acta Neurol Scand. 2002 Aug;106(2):84-92.

PMID:
12100367
11.
12.

Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.

Schädlich PK, Kentsch M, Weber M, Kämmerer W, Brecht JG, Nadipelli V, Huppertz E.

Pharmacoeconomics. 2006;24(6):571-91.

PMID:
16761905
13.

Hospital-based costs associated with venous thromboembolism treatment regimens.

Merli G, Ferrufino C, Lin J, Hussein M, Battleman D.

J Thromb Haemost. 2008 Jul;6(7):1077-86. doi: 10.1111/j.1538-7836.2008.02997.x. Epub 2008 Jul 1.

15.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
16.

Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.

Laporte S, Liotier J, Bertoletti L, Kleber FX, Pineo GF, Chapelle C, Moulin N, Mismetti P.

J Thromb Haemost. 2011 Mar;9(3):464-72. doi: 10.1111/j.1538-7836.2011.04182.x.

17.

Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.

Argenta C, Ferreira MA, Sander GB, Moreira LB.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S89-92. doi: 10.1016/j.jval.2011.05.017.

19.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
20.

Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.

Nutescu EA, Steinmetz Pater K.

Expert Opin Pharmacother. 2008 Jan;9(1):95-105. Review.

PMID:
18076341
Items per page

Supplemental Content

Write to the Help Desk